Dengue Virus Serotype 4 VLP, Recombinant
Catalog No : USB-301169
1256.36€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Dengue Virus Serotype 4 VLP, Recombinant | ||
|---|---|---|---|
| Catalog No | USB-301169 | ||
| Supplier’s Catalog No | 301169 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, 293 human cells | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (SDS-PAGE) | ||
| Form | Supplied as a liquid in PBS, pH 7.4, 30% sucrose. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (SDS-PAGE) | ||
| Description | Dengue Virus Serotype 4 VLP (Virus-Like Particle) is a new, unique product that has been developed in response to the need for highly immunogenic dengue antigens for use in dengue focussed disease research and vaccine development (including use as an immunogen). Like its related product, Dengue Virus Serotype 4 NS1, the Dengue Virus Serotype 4 VLP is produced in human cell lines using state-of-the-art expression techniques. The Dengue Virus Serotype 4 VLP is constructed from E, M and preM proteins, with secretion from the cell aided by substituting the C terminal 20% with the corresponding Japanese Encephalitis Virus sequence (all internal/transmembrane). Concentration and purification is then performed by a series of ultracentrifuge and chromatographical methods which result in VLPs of exceptional quality and purity. Cleavage of preM protein occurs naturally by furin in the cell and results in a dual population of preM and M-containing VLPs. Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others. With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics (ref WHO for Guidelines for Diagnosis, Treatment, Prevention & Control, 2009) As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus. Source: Recombinant Dengue Virus Serotype 4 VLP, strain Dominica/814669/1981, consisting of envelope, pre-membrane, and membrane protein, expressed in 293 human cells. Storage and Stability: Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. | ||
Product Details
© 2020 Imugex All Rights Reserved